Gensight Biologics S.a annual total liabilities
2020
2021
2022
2023
2024
2025
Gensight Biologics S.a Total Liabilities Growth & History (SIGHT)
Gensight Biologics S.a's total liabilities was €33.2M for fiscal 2025.
View full Gensight Biologics S.a company overviewGensight Biologics S.a annual total liabilities history
| Fiscal year | Period ended | Total liabilities | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | €33.2M | −€4.5M | −11.89% |
| 2024 | 2024-12-31 | €37.7M | −€2.2M | −5.42% |
| 2023 | 2023-12-31 | €39.8M | −€1.4M | −3.36% |
| 2022 | 2022-12-31 | €41.2M | €560,000 | +1.38% |
| 2021 | 2021-12-31 | €40.7M | €5.0M | +14.17% |
| 2020 | 2020-12-31 | €35.6M | — | — |
Gensight Biologics S.a quarterly total liabilities
Q4.24
Q4.25
| Fiscal quarter | Period ended | Total liabilities | Change | YoY change |
|---|---|---|---|---|
| Q4 2025 | 2025-12-31 | €33.2M | −€4.5M | −11.89% |
| Q4 2024 | 2024-12-31 | €37.7M | — | — |
Gensight Biologics S.a total liabilities trends
Over the last five fiscal years, Gensight Biologics S.a's total liabilities decreased from €35.6M to €33.2M, a change of −€2.4M. The latest reported quarter, Q4 2025, shows €33.2M.
About the metric
What total liabilities mean
Total liabilities are all obligations reported on a company’s balance sheet, including debt, accounts payable, accrued expenses, deferred revenue, lease liabilities, and other current and long-term obligations.
Calculation and source
reported and calculated total liabilities
TickerStat uses total liabilities reported in company official filings when available. Otherwise, it calculates total liabilities as aligned total assets minus total equity for the same balance-sheet date. Total liabilities should not be confused with interest-bearing debt. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Gensight Biologics S.a source filings ↗Community posts
GenSight advances LUMEVOQ manufacturing transfer to Catalent
GenSight ($SIGHT) said an engineering batch of GS010/LUMEVOQ at Catalent was produced as planned, with viral genome concentration meeting target specifications. Preparations have begun for a GMP-standard batch to supply special-access progr ...